Are Estring® and Vagifem® Equally Effective and Safe for the Treatment of Urogenital Atrophy in Breast Cancer Patients on Aromatase Inhibitor Therapy?

Clinical Oncology

Volumn 24, Issue 8, 2012, Pages

  Simmons, C E ^a   Kuchuk, I ^b,c   Freedman, O C ^d   Colgan, T ^e   Dodd, A ^f,g   Kulhanek, K ^f,g   Sheiner, J ^f,g   Dranitsaris, G ^f,g   Dowsett, M ^h   Folkerd, E ^h   Clemons, M J ^b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d LAKERIDGE HEALTH CORPORATION   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; POLYCARBOPHIL;

ATROPHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LETTER; PH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE;

ADMINISTRATION, INTRAVAGINAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS;

EID: 84865986015     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.06.009     Document Type: Letter

References (3)

1. Morales L., Neven P., Timmerman D., et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-cancer Drugs 2004, 15(8):753-760.
2. Trinkaus M., Chin S., Wolfman W., Simmons C., Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?. Oncologist 2008, 13:222-231.
3. A comparative study of Estring and Vagifem in the treatment of urogenital atrophy in breast cancer patients: the EVA study. Protocol ID OCT1172, 00000009. Available at: [accessed 20.11.08]. http://www.ontariocancertrials.ca.